The common antidepressant Prozac melts away glioblastoma tumors in laboratory mice, suggesting possible treatment for the deadly cancer.
Neurosurgeon Michael Lim studies how to unleash the immune system to attack a type of brain cancer called glioblastoma.
A common ovarian cancer evades detection by convincing nearby immune cells to treat it as a developing fetus.
Stanford Medicine researchers conducted an experiment to find new genes that, when knocked out, boost immune cells' cancer-killing ability.
Stanford Medicine Scientists have devised a blood test to predict some cancer relapses after patients have already been treated.
A new way to deliver mRNA as a COVID-19 vaccine may avoid side effects and increase customization to prevent infection.
Anthony Oro is devoted to understanding the origin of basal cell carcinomas. Now he's found how some become resistant to a common treatment.
Induced pluripotent stem cells share proteins with some cancers. The cells can be used as a vaccine to prevent pancreatic cancers in mice.
As risk factors such as no health insurance and low income accumulate, colorectal cancer patients are less likely to finish chemotherapy.
Stanford Medicine researchers discover that certain proteins can predict survival for patients with a type of eye cancer.
'Resting' exhausted cancer-fighting immune cells enhances their tumor-killing activity, which may help people with blood and solid cancers.
A cancer survivor treated at Stanford has written a book to help kids facing stem cell transplant understand the procedure and approach it with courage.
People who have their first colonoscopy between the age of 45 and 49 halve their risk of subsequent colorectal cancers, a Stanford Medicine study has found.
Editor's update: Emily Ashkin is featured in a podcast from The Lasker Foundation. My legs were starting to ache from standing by my research poster …
Ovarian cancer genetic testing is underused and large gene panels lead to uncertain results, particularly for non-white patients, a Stanford Medicine study finds.
A Stanford-developed anti-cancer therapy currently in clinical trials may also reduce vascular inflammation in heart disease.